Published in Biochem Biophys Res Commun on May 16, 1984
Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. J Neurosci (2001) 2.85
Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun (1971) 2.67
Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet (1974) 2.65
Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet (1985) 2.51
Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science (1971) 2.43
Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A (1982) 2.38
Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun (1971) 2.29
Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med (2002) 2.13
Circulating insulin-like growth factor I mediates effects of exercise on the brain. J Neurosci (2000) 2.11
Somatostatin: abundance of immunoreactive hormone in rat stomach and pancreas. Science (1975) 2.00
Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. J Neurosci (2001) 1.99
Isolation and properties of porcine thyrotropin-releasing hormone. J Biol Chem (1969) 1.97
Neutrophil rolling altered by inhibition of L-selectin shedding in vitro. Nature (1996) 1.90
Insulin-like growth factor I is required for vessel remodeling in the adult brain. Proc Natl Acad Sci U S A (2004) 1.75
Effect of growth hormone release-inhibiting hormone on gastric secretion, mucosal blood flow, and serum gastrin. Gastroenterology (1976) 1.74
Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet (1974) 1.71
Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly. Lancet (1973) 1.68
Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer (1997) 1.64
The identity of chemical and hormonal properties of the thyrotropin releasing hormone and pyroglutamyl-histidyl-proline amide. Biochem Biophys Res Commun (1969) 1.62
Hypothalamic regulatory hormones. Annu Rev Biochem (1978) 1.60
Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes (2001) 1.59
Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci U S A (1986) 1.59
Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci U S A (2000) 1.57
Isolation and structure of pro-somatostatin: a putative somatostatin precursor from pig hypothalamus. Proc Natl Acad Sci U S A (1980) 1.54
Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A (1989) 1.52
Human ovarian cancers express somatostatin receptors. J Clin Endocrinol Metab (2000) 1.49
Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci U S A (1984) 1.49
The regional distribution of somatostatin in the rat brain. Endocrinology (1975) 1.48
Activity and specificity of synthetic thyrotropin-releasing hormone in man. Biochem Biophys Res Commun (1970) 1.47
Some notes on the background of the isolation, determination of structure, synthesis, and early clinical trials of the luteinizing hormone- and follicle-stimulating hormone-releasing hormone. Am J Obstet Gynecol (1976) 1.47
Isolation and structure of somatostatin from porcine hypothalami. Biochemistry (1976) 1.46
Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci U S A (1989) 1.45
Solid phase synthesis of growth hormone-release inhibiting factor. Biochem Biophys Res Commun (1973) 1.44
Isolation and structure of hypothalamic MSH release-inhibition hormone. Biochem Biophys Res Commun (1971) 1.43
The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod (1994) 1.41
Hypothalamic regulatory hormones. Science (1973) 1.41
New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. Int J Pept Protein Res (1988) 1.41
Synthetic thyrotropin-releasing hormone. A potent stimulator of thyrotropin secretion in man. N Engl J Med (1971) 1.40
Hypothalamic neurohormones regulating anterior pituitary function. Recent Prog Horm Res (1968) 1.36
Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules. Proc Natl Acad Sci U S A (1984) 1.35
Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. J Natl Cancer Inst (1995) 1.35
Hypothalamic follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-regulating hormone: structure, physiology, and clinical studies. Fertil Steril (1971) 1.35
Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci U S A (1995) 1.35
Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A (1981) 1.34
Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc Soc Exp Biol Med (1984) 1.33
Shedding of the lymphocyte L-selectin adhesion molecule is inhibited by a hydroxamic acid-based protease inhibitor. Identification with an L-selectin-alkaline phosphatase reporter. J Biol Chem (1996) 1.30
The hypothalamus and reproduction. Am J Obstet Gynecol (1972) 1.29
Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res (1998) 1.28
Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal (1989) 1.28
Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone. Proc Natl Acad Sci U S A (1995) 1.27
Interaction between hypothalamic peptides in a superfused pituitary cell system. Peptides (1984) 1.27
Radioimmunoassay for GH-release inhibiting hormone. Proc Soc Exp Biol Med (1975) 1.27
Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line. FEBS Lett (1985) 1.26
Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone. Proc Natl Acad Sci U S A (1999) 1.25
Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc Natl Acad Sci U S A (1997) 1.25
Central actions of liver-derived insulin-like growth factor I underlying its pro-cognitive effects. Mol Psychiatry (2007) 1.25
LH-RH agonists and antagonists. Int J Gynaecol Obstet (1980) 1.24
Growth hormone release inhibiting hormone in acromegaly. Br Med J (1974) 1.24
Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma. Proc Natl Acad Sci U S A (1999) 1.23
DOPA potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF). Life Sci I (1971) 1.23
Radioimmunoassay of somatostatin. Metabolism (1978) 1.22
Immunocytochemical localization of corticotropin-releasing factor (CRF) in the rat brain. Am J Anat (1982) 1.22
High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab (1993) 1.22
Effect of growth hormone-release inhibiting hormone on hormones stimulating exocrine pancreatic secretion. J Clin Invest (1976) 1.22
Clinical experience with hypothalamic releasing hormones. 1. Thyrotropin-releasing hormone. Recent Prog Horm Res (1972) 1.21
Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc Natl Acad Sci U S A (1999) 1.21
Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol Aging (2005) 1.20
Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors. Proc Natl Acad Sci U S A (1998) 1.20
Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med (1998) 1.20
Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci U S A (1994) 1.19
Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci U S A (2000) 1.19
Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci U S A (1996) 1.17
Stimulation of release and synthesis of luteinizing hormone(LH) and follicle stimulating hormone(FSH) in tissue culture of rat pituitaries in response to natural and synthetic LH and FSH releasing hormone. Endocrinology (1972) 1.17
High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol (2000) 1.16
Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci U S A (1994) 1.16
Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc Natl Acad Sci U S A (1999) 1.16
Structure of porcine thyrotropin releasing hormone. Biochemistry (1970) 1.15
The amino acid sequence of a peptide with growth hormone-releasing activity isolated from porcine hypothalamus. J Biol Chem (1971) 1.15
Use of radioreceptor assay and cell superfusion system for in vitro screening of analogs of growth hormone-releasing hormone. Receptor (1993) 1.15
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Br J Cancer (2000) 1.15
Corticotrophin releasing factor: responses in normal subjects and patients with disorders of the hypothalamus and pituitary. Clin Endocrinol (Oxf) (1984) 1.15
Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J Clin Endocrinol Metab (1999) 1.14
Aspects of hypothalamic regulation of the pituitary gland. Science (1978) 1.14
Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice. Breast Cancer Res Treat (2000) 1.13
Clinical experience with hypothalamic releasing hormones. 2. Luteinizing hormone-releasing hormone and other hypophysiotropic releasing hormones. Recent Prog Horm Res (1972) 1.13
Letter: Immunohistochemical localization of somatostatin in the rat pancreas. J Histochem Cytochem (1975) 1.12
Physiological role of somatostatin in the control of growth hormone and thyrotropin secretion. Biochem Biophys Res Commun (1976) 1.12
Neurodegeneration is associated to changes in serum insulin-like growth factors. Neurobiol Dis (2000) 1.12
Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects. Proc Natl Acad Sci U S A (1988) 1.11
Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. Br J Cancer (1997) 1.11
High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc Natl Acad Sci U S A (1996) 1.11
Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. Cancer Treat Rep (1984) 1.10
Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression. Cancer (1990) 1.10
Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6. J Med Chem (1976) 1.10
Suppression of prolactin release by a purified porcine PIF preparation and catecholamines infused into a rat hypophysial portal vessel. Endocrinology (1974) 1.10
Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod (1995) 1.09
Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A (1989) 1.09
sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. J Biol Chem (1999) 1.08
Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. Proc Natl Acad Sci U S A (2000) 1.07
Highly active position eight analogues of somatostatin and separation of peptide diastereomers by partition chromatography. Biochemistry (1978) 1.07